Forte Biosciences Stock
Forte Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Paul A. Wagner
- Employees
- 23
- Market cap
- $1.6 B
- IPO
- 13/04/2017
Forte Biosciences, Inc. is a biopharmaceutical company based in Dallas, USA, operating within the Healthcare sector and the Biotechnology industry. The firm is currently in its clinical development phase. A key initiative for the company involves advancing the FB-102 program, which is specifically designed to tackle a…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Forte Biosciences stock: price history
1D
+0.0%
1W
+0.1%
1M
+0.6%
6M
+154.8%
YTD
+182.3%
1Y
+585.6%
2Y
+896.0%
5Y
-89.1%
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~24% weaker price swings than usual
Forte Biosciences stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 11/09/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
1 more assignment (Enabler/Second row) Pro-only.
Forte Biosciences Inc. is a US-based biopharmaceutical company currently in the clinical development stage. The company's focus lies on the advancement of the FB-102 program, which is designed for the treatment of autoimmune diseases such as vitiligo and alopecia areata. As the company is primarily in the research phase, it currently generates no revenue from commercial product sales.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Forte Biosciences
Analyst assessment of Forte Biosciences
PRICE TARGET LOW
US$77.00
CONSENSUS
US$77.00
MEDIAN
US$77.00
PRICE TARGET HIGH
US$77.00
0
STRONG BUY
3
BUY
4
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Hold
As of: 28/07/2026
Forte Biosciences stock metrics
P/E
-16.77
P/B
9.96
EV/EBITDA
-18.37
RETURN ON EQUITY
-12.7%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
87.1%
FLOAT SHARES
17,852,834
AVG. DAILY VOLUME (30D)
2,092,318
Insider transactions (SEC)
Kornfeld Steven
GRYSKA DAVID W
Riley Antony A
Wagner Paul A.
Riley Antony A
Attention
Price since yesterday: +0.0%
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Forte Biosciences stock
What does Forte Biosciences do?
Forte Biosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Paul A. Wagner, the company employs around 23 people.
The IPO was on 13/04/2017; the stock trades on NASDAQ under the ticker FBRX.
What do analysts say about Forte Biosciences stock?
7 analysts rate the stock, the consensus is Hold (as of 28/07/2026).
The average price target is US$77.00, ranging from US$77.00 to US$77.00, with a median of US$77.00.
This is an external assessment, not a statement by Market Jury.
When does Forte Biosciences report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly -24% stronger than usual.
Does Forte Biosciences pay a dividend?
No, Forte Biosciences currently does not pay a dividend.
Which stocks are comparable to Forte Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Forte Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Forte Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.